Clinical trials can present many challenges for patients–particularly injections. Oliver Eden, senior business unit director at Jabil, and Travis Webb, chief scientific officer at PII, discuss nuance, challenges and opportunities of autoinjectors and combination drug delivery systems. Additionally, they advocate that drug delivery systems enter the conversation earlier in clinical development stages given interdependencies.  This episode is presented in partnership with <a href="https://www.pharm-int.com/">PII</a>. Host<a href="https://www.linkedin.com/in/lorielliskatz/">⁠⁠⁠⁠⁠⁠⁠⁠⁠Lori Ellis⁠⁠⁠⁠⁠⁠⁠⁠⁠</a>, Head of Insights, BioSpace Guests<a href="https://www.linkedin.com/in/oliver-eden-58040412/">Oliver Eden</a>, Senior Business Unit Director, Jabil<a href="https://www.linkedin.com/in/travis-webb-a2464056/">Travis Webb</a>, Chief Scientific Officer, PII Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

Shutdown Pauses New Drug Reviews, CDC Issues New COVID Guidance, CGT Meets on Mesa

Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.